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 Abstract 
 Background: Stereotactic body radiation therapy (SBRT) is an advanced technique of external 
beam radiation therapy that delivers large ablative doses of radiation. In the past decade, 
many cancer centers have adopted SBRT as one mode of radically treating small-sized hepa-
tocellular carcinoma (HCC), based on encouraging clinical outcomes. SBRT thus seems reason-
able as first-line treatment of inoperable HCC confined to the liver. However, most of the 
clinical studies to date have been retrospective in nature, with key issues still under investiga-
tion.  Summary: The above-mentioned publications were subjected to scrutiny, fueling dis-
cussions at the 7th Asia-Pacific Primary Liver Cancer Expert (APPLE 2016) Meeting on various 
clinical variables, such as indications for SBRT, therapeutic outcomes, treatment-related tox-
icities, doses prescribed, and specific techniques. The consensus reached should be of interest 
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to all professionals active in the treatment of HCC, especially radiation oncologists.  Key Mes-
sages: SBRT is a safe and effective therapeutic option for patients with small-sized HCC, of-
fering substantial local control, improved overall survival, and low toxicity. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 As diagnostic imaging and screening programs for hepatocellular carcinoma (HCC) have 
progressed, early-stage or small-sized tumors are being detected with greater frequency, 
enabling treatment locally via surgical resection, radiofrequency ablation (RFA), or transar-
terial chemoembolization (TACE). Recent technological advances offer precise and safe radi-
ation delivery to multiple tumors in the body through image guidance. Given that the liver is 
a parallel organ, relatively high locally ablative radiation doses are tolerated. There is growing 
evidence for the usefulness of stereotactic body radiation therapy (SBRT) in the management 
of patients with primary liver cancer. The consensus presented herein was developed on the 
basis of recent evidence and expert opinions.
 Definition 
 SBRT is a type of external beam radiation therapy technique requiring special equipment 
for use in patient positioning and delivery of high-dose radiation to body tumors (excluding 
the brain). Fewer fractions and sharp dose gradients spare normal tissues. This complex tech-
nique relies on the following: (1) stringent control of breathing motion, engaging 4-dimen-
sional (4D) computed tomography (CT) scans to track respiration-induced hepatic move-
ment, (2) extreme precision in patient positioning, and (3) image guidance for radiation de-
livery  [1] .
 Early-stage HCC is defined as a solitary tumor  ≤ 5 cm in maximum diameter or as multiple 
nodules ( ≤ 3 total) measuring  ≤ 3 cm in maximum diameter, without vascular invasion/extra-
hepatic metastasis and with Child-Pugh A or B hepatic function. Not all tumors of small size 
are qualified as early stage because intrahepatic recurrences of HCC or Child-Pugh C score 
may apply  [2, 3] .
 Indications for SBRT 
 SBRT may be an effective therapeutic option for early-stage or small-sized HCC, espe-
cially if surgical resection or percutaneous ablative therapies are difficult, unfeasible, or 
rejected. This approach is also used as a salvage treatment for tumor recurrence after local 
radical therapies or for residual cancer after surgical resection or percutaneous ablative 
attempts. In addition, SBRT may act as a bridge to liver transplantation or serve as an adjuvant 
treatment for intrahepatic tumors with incomplete iodized oil retention.
 Outcomes of SBRT Use for HCC 
 Survival 
 SBRT has emerged as a promising noninvasive therapy in this setting. A limited number 
of clinical trials examining SBRT use in patients with HCC have been reported, yielding 3-year 
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overall survival (OS) rates of 54–70%  [4, 5] and a 5-year OS rate of 64% in small-sized HCC 
 [6] . However, such efforts have been limited by small patient numbers and retrospective 
inclusion of nonsurgical patients. Published results of several retrospective studies ( Table 1 ) 
have largely included instances in which surgical resection or percutaneous ablative ther-
apies were difficult, unfeasible, or rejected, as well as some pools of intermediate or advanced-
stage HCC. Herein, only patients receiving  ≤ 10 fractions for HCC were reviewed.
 A total of 224 patients with inoperable, nonmetastatic HCC received treatments at 
Michigan University Medical Center (RFA, 161; image-guided SBRT, 63). Inverse probability 
of treatment weighting was applied to adjust for imbalances in treatment assignment. In 
multivariate analysis, OS rates for RFA (1 year, 69.6%; 2 years, 52.9%) and SBRT (1 year, 
74.1%; 2 years, 46.3%) did not differ significantly. Although based on retrospective data, 
SBRT nonetheless appears reasonable as first-line treatment of inoperable HCC, especially for 
tumors >2 cm  [7] .
 With adjustment for presumptive prognostic factors, Huang et al.  [8] used a Cox multi-
variable regression hazard model to compare OS curves of SBRT ( n = 36) and non-SBRT ( n = 
138) patient groups (hazard ratio = 2.44;  p = 0.005). The authors also compared the 2-year 
OS rates of SBRT recipients ( n = 28) and matched controls ( n = 28) (72.6 vs. 42.1%;  p = 0.013), 
concluding that SBRT improved survival in patients with recurrent unresectable HCC.
 In  Table 2 , survival data for patients with small-sized HCC are stratified by locoregional 
treatment modality. The current options for curative treatment of early-stage or small-sized 
HCC, namely liver transplantation, surgical resection, TACE, and percutaneous tumor ablation, 
all conform to established authoritative guidelines (i.e., Milan criteria, Barcelona Clinic Liver 
Cancer staging)  [9] . Five-year survival rates of 50–80% are thereby achieved  [10] . Given 
comparable outcomes (as shown), SBRT constitutes a viable alternative if such therapies fail 
or cannot be applied.
 SBRT is also a suitable bridging therapy for patients with HCC awaiting liver transplan-
tation. At the University of Rochester Medical Center, successful orthotopic liver transplan-
tation was undertaken following SBRT (median, 6.3 months) in 11 of 18 patients with HCC 
(21 intrahepatic lesions). Recipients had small-sized HCC and Child-Pugh B or C liver function 
 [11] . Similarly, 10 patients with HCC (11 lesions) underwent SBRT at Baylor University, 
administered as a bridge to liver transplantation. All patients subsequently received liver 
transplants  [12] . SBRT may enable patients with HCC to remain eligible for curative trans-
plantation pending organ availability.
 Table 2. Comparison of overall survival for small-sized hepatocellular carcinoma treated with locoregional 
therapies
Treatment modality 3-year survival 5-year survival
Surgical resection 75 – 90% [9, 52] 40 – 75% [10, 52]
Laparoscopic resection 70 – 93% [54] 50 – 71% [54]
Radiofrequency ablation 54 – 67.2% [53] 40 – 67.9% [10, 55]
Liver transplantation 65 – 85% [59] 65 – 80% [59]
Stereotactic body radiation therapy 54 – 70% [4, 5] 64% [6]
Reference 4: the hepatocellular carcinoma was <6 cm across its longest diameter, and ≤3 lesions were 
presented. Reference 5: a single (either solitary or recurrent) hepatocellular carcinoma lesion; unfeasible, 
difficult, or refusal to undergo other surgery or percutaneous ablative therapies, tumor ≤5 cm. Reference 6: 
maximum diameter ≤5 cm. Reference 10: intrahepatic tumor with single nodule ≤5 cm or up to 3 nodules 
<3 cm. Reference 53: up to 2 nodules <4 cm. Reference 55: up to 3 nodules with a maximum diameter of 5 cm.
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 Toxicity 
 In terms of acute adverse events, the most common subjective complaints are consti-
tutional symptoms, including fatigue, poor appetite, and nausea. Slight elevation of liver 
enzymes and leukopenia/thrombocytopenia are the main objective findings. Once SBRT is 
completed, acute events typically resolve without specific treatment. Nonclassic radiation-
induced liver disease (RILD) (liver enzyme elevation,  ≥ 2-point rise in Child-Pugh score) is 
also common during or after SBRT but is rarely fatal. As shown in  Table 3 , a summary of 15 
reports and 1,063 patients with HCC undergoing SBRT, only 8 patients (0.8%) presented with 
grade 5 liver failure, and most fatalities from liver failure were linked with Child-Pugh B liver 
function. Caution is thus warranted in patients with Child-Pugh B status, ensuring low dose 
volumes.
 Gastrointestinal (GI) toxicity is another concern, especially if tumors and luminal struc-
tures (esophagus, stomach, duodenum, or intestine) are closely situated. GI toxicities of grade 
3 or higher were reported in 15 patients (1.4%) ( Table 3 ). Other complications, such as rib 
fracture, chest or abdominal pain, biliary stricture, and musculoskeletal discomfort, were 
noted occasionally. However, toxicities in general were infrequent and mild.
 Radiation Dose 
 Tumor Dose 
 SBRT is an ablative therapy using higher doses to destroy cancer cells. Delivery protocols 
have varied considerably (24–60 Gy/3–10 fractions). High-dose SBRT may increase local 
control and improve OS in patients with inoperable HCC. Jang et al.  [13] cited respective 
2-year local control/OS rates of 100/71, 78/64, and 64/30% ( p = 0.009/ p < 0.001) at doses 
>54, 45–54, and <45 Gy, all in 3 fractions. SBRT dose was also found to be significantly prog-
nostic of OS ( p = 0.005) in multivariate analysis, and correlation analysis revealed a positive 
linear relationship between SBRT dose and local control ( R = 0.899;  p = 0.006)/OS ( R = 0.940; 
 p = 0.002) at 2 years. Wahl et al.  [7] further documented local control rates of 97.4 and 83.8% 
at 1 and 2 years, respectively, using a median biologically equivalent dose (BED) of 100 Gy, 
assuming a 10 Gy α/β ratio. In most instances, BED 10 >80 Gy was delivered to tumors ( Table 1 ). 
Dose and fractions were usually dictated by tumor size, organs at risk (such as whole liver), 
and luminal structures nearby. Unfortunately, no evidence has yet emerged to clearly support 
a minimum or maximum dose of SBRT for HCC. This issue merits further research.
 Dose Constraints for Normal Liver 
 Su et al.  [6] , Yoon et al.  [4] , and Jang et al.  [13] from Asia indicated that liver volume 
receiving 15 Gy (V15) >700 mL may lead to grade 3 or fatal RILD at doses of 30–60 Gy/3–6 
fractions, but according to Bibault et al.  [14] in France, no RILD was encountered at whole 
normal liver volume >700 mL and V15 <50%, using 40–50 Gy/3 fractions. However, decom-
pensated cirrhosis did develop 3 months later in 5 patients (6.6%). At normal liver volume 
<700 mL and mean hepatic dose <15 Gy (25–48 Gy/4–5 fractions), 2 of the 26 patients studied 
by Huang et al.  [8] developed RILD, but both recovered with supportive care. Still, Katz et al. 
 [11] reported no RILD at normal liver volume  ≥ 1,000 mL and mean dose <15 Gy (50 Gy/
10 fractions). Therefore, at least 700 mL of normal liver (Child-Pugh A) must receive <15 Gy 
to minimize acute and late liver toxicities  [15] .
 Dose Constraints for the GI Tract and Other Organs at Risk 
 GI bleeding is the most frequently encountered nonhepatic toxicity following SBRT. With 
delivery of <25 Gy to 1 mL of duodenum, stomach, or small bowel, the rate of GI bleeding was 
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3.0% (4/132)  [6] . This incidence declined to 1.6% at doses <24 Gy in 3 fractions or 27.5 Gy 
in 5 fractions per 0.5 mL  [7] , and GI ulcers developed in 3.9% (3/77)  [16] . At <21 Gy/3 frac-
tions delivered to 5 mL of stomach or <24 Gy/3 fractions delivered to 0.5 mL of duodenum, 
GI toxicity was minimal (grade 2, 3/75; grade 4, 1/75)  [14] . Doses <25, <24, and <23 Gy, 
respectively delivered to 5 mL of stomach or intestine in 36 patients were associated with a 
single instance of gastric ulcer  [8] . GI dose constraints should be considered for neighboring 
hepatic tumors. Compounding the effects of radiation, patients with underlying cirrhosis are 
at risk of gastroduodenal bleeding or ulcers. Yet, fatal GI toxicity (bleeding, ulceration, or 
perforation) was rarely reported ( Table 3 ), largely because most doses delivered to 1 mL of 
esophagus, stomach, duodenum, or intestine were <24 Gy/3 fractions or <30 Gy/6 fractions. 
In other words, fatal GI toxicity was avoidable with appropriate constraints.
 No data on radiation-induced injury to the kidney, heart, or spinal cord were available, 
these organs being remotely situated. In tumors located close to ribs, whole-rib doses should 
be <30 Gy/3 fractions  [4] .
 Combination with Other Therapies 
 Jacob et al.  [17] retrospectively compared TACE alone and TACE plus SBRT as treatment 
of HCC in patients with tumor diameters  ≥ 3 cm. Local recurrences were significantly reduced 
and OS improved by combined treatment. Honda et al.  [18] also recorded a rise in complete 
responses upon addition of SBRT to TACE in patients with solitary HCC  ≤ 3 cm, and in patients 
subjected to SBRT after incomplete response to TACE, the survival outcomes registered by 
Paik et al.  [19] approached those of complete TACE responders or curative measures. SBRT 
as adjuvant therapy may well improve the efficacy of TACE, but no clinical data at present 
suggest that TACE improves the efficacy of SBRT in early-stage HCC.
 SBRT may also serve as a salvage treatment for residual or recurrent HCC after surgical 
resection or RFA. However, significant toxicity has resulted from SBRT and sorafenib in 
combination, with no added benefit. Thus, a regimen of concurrent SBRT and sorafenib is not 
recommended outside a clinical trial in locally advanced HCC  [20] . Patients with hepatitis B 
virus reactivation and concomitant serum hepatitis B virus DNA elevation or biochemical 
abnormalities of the liver are advised to receive antiviral therapies prior to SBRT.
 SBRT Technique 
 Simulation and Target Delineation 
 Dynamic contrast-enhanced CT is the preferred imaging modality for treatment planning. 
If tumors are not well visualized on CT scan, fusion of pretreatment diagnostic magnetic reso-
nance imaging and planning CT images is required. 4D CT simulations are used in patients 
treated via nonbreathhold technique to gauge gross tumor volume and internal target volume. 
In SBRT, gross tumor volume, clinical target volume, internal target volume, and planning 
target volume are stipulated by ICRU Report 62  [21] . Although subclinical extension of HCC 
is a known phenomenon  [22] , clinical target volume margin is generally not critical in SBRT, 
because falloff exposure will likely eradicate any existing microscopic disease. If respiratory 
gating is applied, internal target volume is the sum of all gross tumor volumes within the 
predefined gating window. Planning target volume margin is a technique- and center-specific 
geometrical variation. The entire liver and both kidneys, as well as the spinal cord, duodenum, 
and stomach, are delineated and should be contoured as organs at risk.
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 Immobilization 
 Patient immobilization and control of organ motion are crucial for the success of SBRT in 
this setting. A variety of body frame systems are available, most relying on vacuum cushions, 
with or without abdominal compression  [23, 24] .
 Methods controlling breathing motion include active breathing control (ABC), abdominal 
compression, respiratory gating, and real-time tumor tracking. ABC involves a modified 
spirometer, with two pairs of flow monitors and scissor valves to control respiration. Acti-
vation is triggered at a predefined lung volume, “freezing” all breathing motion for 15–20 s 
by closing both valves. ABC-assisted SBRT is quick, generating the smallest planning target 
volume by comparison. However, pretreatment training is required, and it may be unsuitable 
for some patients, especially those with reduced lung function  [25] .
 Abdominal compression is a convenient mean of reducing tumor motion by applying a 
compressive plate or a breath belt during both planning CT and treatment. High levels of 
forces are required to compress the abdomen  [26] , and subxiphoid compression is advised 
for better breathing management, reducing craniocaudal liver motion to within 5 mm  [27] . 
However, liver deformation and gross tumor volume positional deviation are important 
consequences of abdominal compression, necessitating rigid liver-to-liver registrations to 
minimize variations  [28] .
 With respiratory gating, SBRT dose is delivered only in specific phases of the respiratory 
cycle to avoid unnecessary dosing of normal tissue and underdosing of the target. Treatment 
time is longer with gating, but it is an acceptable alternative to ABC. The Real-Time Position 
Management System or the Exac Trac Adaptive Gating System are commonly used.
 Image Guidance 
 Various imaging modalities are integrated into radiation treatment systems, offering 
image guidance strategies to produce volumetric and/or planar imaging at the time of 
treatment delivery and to reduce the negative impact of geometrical changes that may occur 
 [29] . For SBRT in HCC, two available clinical systems enabling tracking of and compensation 
for patient-specific tumor motion during treatment are the gimbal-based Vero platform and 
the robot-based CyberKnife  [30] . Due to limited tumor visualization in treatment CT scans 
and X-ray fluoroscopic images, gold fiducial markers are often implanted in liver tissue 
surrounding tumors to reduce residual setup errors  [31] , assess breathing motion  [32] , and 
track tumor position dynamically  [33] .
 Image-guided radiation delivery is fundamental to SBRT. At present, a number of ap-
plications, such as CyberKnife, helical tomotherapy, and volumetric-modulated arc radio-
therapy, are SBRT capable  [34] .
 Treatment Plan 
 During the past decade, various techniques have been devised for SBRT of HCC. Compared 
with other methods (3D conformal radiotherapy or intensity-modulated radiation therapy), 
SBRT plans have very high dose drop speeds around targets and high conformal doses to 
targets. Tumor volumes are also smaller. Hence, a small grid size (typically 2 mm) is recom-
mended for dose calculation  [1] , and at least 5–9 noncoplanar or coplanar fields should be 
used for conventional treatment planning  [35] . Small-size beam shaping devices may improve 
conformity of target dose distributions  [1] . In some protocols, tissue heterogeneity correc-
tions are included in dose calculations (RTOG1112). Various indices can be applied to evaluate 
and report plan quality (e.g., conformity index, R50%, D 2 cm, and heterogeneity index)  [1] . 
The gradient index (same as R50%) reflects the dose gradient around the planning target 
volume  [36] , impacting nearby normal tissue. Hot spots within the target are generally 
considered a mark of steep dose gradient and are clinically desirable. Considering the differ-
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ences among techniques or protocols, it is essential to report the prescription dose in details 
(e.g., isodose covering planning target volume to a particular volume).
 Post-SBRT Images 
 Tumor 
 HCC responsive to SBRT appears nonenhanced on imaging, which may be more useful 
than size reduction in evaluating treatment outcomes during the first 6–12 months (supporting 
EASL rather than RECIST criteria)  [37] . Response rates in hypervascular HCC have increased 
during follow-up radiologic imaging for as much as to 2 years after completion of SBRT  [38] .
 Liver 
 In patients receiving SBRT for HCC, follow-up CT liver dynamics were classifiable as 
follows: type 1, hyperdensity in all enhanced phases; type 2, hypodensity in arterial and 
portal phases; and type 3, isodensity in all enhanced phases  [39, 40] . Features in the 
enhancement group (type 1) changed significantly over time, most patients qualifying as 
Child-Pugh A. In the nonenhancement group (type 3), Child-Pugh B was a significant element 
 [39, 40] . The incidence of arterial hypervascularity in irradiated hepatic parenchyma may 
gradually increase for 6 months after SBRT, potentially interfering with accurate assessment 
of treatment response. Lack of washout on delayed phase in hypervascular areas helps distin-
guish SBRT-related change from residual/recurrent HCC  [41] . Focal liver reaction to SBRT 
(not to be misread as recurrent HCC) has a threshold dose of 30 Gy/5 fractions for Child-Pugh 
A and 25 Gy/5 fractions for Child-Pugh B  [42, 43] or 20 Gy/3 fractions  [44] . Of note, uncer-
tainty exists between the imaging changes, the pathological fibrosis, and the serological data. 
These doses will help predict potential loss of liver tissue after SBRT.
 Conclusion 
 In conclusion, SBRT is a safe and effective therapeutic option for patients with small-
sized HCC, offering substantial local control, improved OS, and low toxicity.
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